Journal of Applied Physiology, Vol 62, Issue 2 429-437, Copyright © 1987 by American Physiological Society

ARTICLES

Artificial pulmonary surfactant inhibited by proteins

T. Fuchimukai, T. Fujiwara, A. Takahashi and G. Enhorning

With a pulsating bubble surfactometer we assessed the ability of various agents, fibrinogen, human serum, albumin, and a 55,000-dalton serum protein, to interfere with the surface activity of Surfactant TA. From a highest final protein concentration of 4 mg/ml the potential inhibitors were diluted down to 0.125 mg/ml in six steps, and each concentration was evaluated together with two final phospholipid concentrations, 6.25 and 1.25 mg/ml, of the surfactant preparation. The strongest inhibiting action was exerted by fibrinogen, followed by human serum and the 55,000-dalton serum protein; the weakest inhibitor was albumin. Bilirubin, when added in an amount of 1.73 mg/100 ml dissolved in human serum, significantly (P less than 0.001) augmented the inhibition over that exerted by human serum alone. Adsorption rate, as reflected in the mean value of surface tension 2 and 10 s after creation of a bubble, not pulsating, was seriously affected by each of the protein-containing inhibitors in concentrations exceeding 1 mg/ml. Surface tension was raised significantly when the pulsating bubble was at maximal and minimal size. The effect was dose dependent. At maximal size it showed no tendency to disappear during the 10-min recording, but at minimal bubble size the inhibition gradually diminished. We conclude that proteins present in the airways may seriously interfere with the activity of Surfactant TA.

This article has been cited by other articles:

				A. Gunther, N. Lubke, M. Ermert, R. T. Schermuly, N. Weissmann, A. Breithecker, P. Markart, C. Ruppert, K. Quanz, L. Ermert, et al. Prevention of Bleomycin-induced Lung Fibrosis by Aerosolization of Heparin or Urokinase in Rabbits Am. J. Respir. Crit. Care Med., December 1, 2003; 168(11): 1358 - 1365. [Abstract] [Full Text] [PDF]

				A. J. Ryan, D. M. McCoy, S. E. McGowan, R. G. Salome, and R. K. Mallampalli Alveolar sphingolipids generated in response to TNF-alpha modifies surfactant biophysical activity J Appl Physiol, January 1, 2003; 94(1): 253 - 258. [Abstract] [Full Text] [PDF]

				M Gupta, J M Hernandez-Juviel, A J Waring, and F J Walther Function and inhibition sensitivity of the N-terminal segment of surfactant protein B (SP-B1-25) in preterm rabbits Thorax, November 1, 2001; 56(11): 871 - 876. [Abstract] [Full Text] [PDF]

				J. G. LAFFEY, M. TANAKA, D. ENGELBERTS, X. LUO, S. YUAN, A. KEITH TANSWELL, M. POST, T. LINDSAY, and B. P. KAVANAGH Therapeutic Hypercapnia Reduces Pulmonary and Systemic Injury following In Vivo Lung Reperfusion Am. J. Respir. Crit. Care Med., December 1, 2000; 162(6): 2287 - 2294. [Abstract] [Full Text]

				S. M. Wright, P. M. Hockey, G. Enhorning, P. Strong, K. B. M. Reid, S. T. Holgate, R. Djukanovic, and A. D. Postle Altered airway surfactant phospholipid composition and reduced lung function in asthma J Appl Physiol, October 1, 2000; 89(4): 1283 - 1292. [Abstract] [Full Text] [PDF]

				P. Rauprich, O. Moller, G. Walter, E. Herting, and B. Robertson Influence of Modified Natural or Synthetic Surfactant Preparations on Growth of Bacteria Causing Infections in the Neonatal Period Clin. Vaccine Immunol., September 1, 2000; 7(5): 817 - 822. [Abstract] [Full Text] [PDF]

				E. L. Heeley, J. M. Hohlfeld, N. Krug, and A. D. Postle Phospholipid molecular species of bronchoalveolar lavage fluid after local allergen challenge in asthma Am J Physiol Lung Cell Mol Physiol, February 1, 2000; 278(2): L305 - L311. [Abstract] [Full Text] [PDF]

				B Jugg, J Jenner, and P Rice The effect of perfluoroisobutene and phosgene on rat lavage fluid surfactant phospholipids Human and Experimental Toxicology, November 1, 1999; 18(11): 659 - 668. [Abstract] [PDF]

				N. N. JARJOUR and G. ENHORNING Antigen-induced Airway Inflammation in Atopic Subjects Generates Dysfunction of Pulmonary Surfactant Am. J. Respir. Crit. Care Med., July 1, 1999; 160(1): 336 - 341. [Abstract] [Full Text]

				T. Kobayashi, K. Ohta, K. Tashiro, K. Nishizuka, W.-M. Chen, S. Ohmura, and K. Yamamoto Dextran restores albumin-inhibited surface activity of pulmonary surfactant extract J Appl Physiol, June 1, 1999; 86(6): 1778 - 1784. [Abstract] [Full Text] [PDF]

				J. M. HOHLFELD, K. AHLF, G. ENHORNING, K. BALKE, V. J. ERPENBECK, J. PETSCHALLIES, H. G. HOYMANN, H. FABEL, and N. KRUG Dysfunction of Pulmonary Surfactant in Asthmatics after Segmental Allergen Challenge Am. J. Respir. Crit. Care Med., June 1, 1999; 159(6): 1803 - 1809. [Abstract] [Full Text]

				Z. WANG and R. H. NOTTER Additivity of Protein and Nonprotein Inhibitors of Lung Surfactant Activity Am. J. Respir. Crit. Care Med., July 1, 1998; 158(1): 28 - 35. [Abstract] [Full Text] [PDF]

				O. V. Lopatko, S. Orgeig, C. B. Daniels, and D. Palmer Alterations in the surface properties of lung surfactant in the torpid marsupial Sminthopsis crassicaudata J Appl Physiol, January 1, 1998; 84(1): 146 - 156. [Abstract] [Full Text] [PDF]

				G. Grossmann, Y. Suzuki, B. Robertson, T. Kobayashi, P. Berggren, W.-Z. Li, G.-W. Song, and B. Sun Pathophysiology of neonatal lung injury induced by monoclonal antibody to surfactant protein B J Appl Physiol, June 1, 1997; 82(6): 2003 - 2010. [Abstract] [Full Text] [PDF]

				J. H. van Blankenstein, C. J Slager, L. K. Soei, H Boersma, T. Stijnen, J.C.H Schuurbiers, R. Krams, B Lachmann, and P. D Verdouw Cardiac depression after experimental air embolism in pigs: role of addition of a surface-active agent Cardiovasc Res, June 1, 1997; 34(3): 473 - 482. [Abstract] [Full Text] [PDF]

				J. G. Weg, R. A. Balk, R. S. Tharratt, S. G. Jenkinson, J. B. Shah, D. Zaccardelli, J. Horton, E. N. Pattishall, the Exosurf ARDS Sepsis Study Group, T. E. Albertson, et al. Safety and Potential Efficacy of an Aerosolized Surfactant in Human Sepsis-Induced Adult Respiratory Distress Syndrome JAMA, November 9, 1994; 272(18): 1433 - 1438. [Abstract] [PDF]